Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc (NQ: DNLI )

27.05 +1.09 (+4.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Denali Therapeutics Inc

< Previous 1 2 3 Next >
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued. 
Via Benzinga
A Biotech Breakout Will Be Led By Small Caps
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever. 
Via Talk Markets
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q2 2024
DNLI stock results show that Denali Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Denali Therapeutics Stock Gets Technical Rating Upgrade
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery. 
Via InvestorPlace
4 Analysts Assess Denali Therapeutics: What You Need To Know
Via Benzinga
Denali Therapeutics: Q4 Earnings Insights
Via Benzinga
The Latest Analyst Ratings for Denali Therapeutics
Via Benzinga
Where Denali Therapeutics Stands With Analysts
Via Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024
DNLI stock results show that Denali Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Analyst Expectations for Denali Therapeutics's Future
Via Benzinga
Where Denali Therapeutics Stands With Analysts
Via Benzinga
Analyst Expectations for Denali Therapeutics's Future
Within the last quarter, Denali Therapeutics (NASDAQ:DNLI) has observed the following analyst ratings: 
Via Benzinga
To the Moon and Beyond: 7 Stocks With Cosmic Potential
With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential. 
Via InvestorPlace
Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know
Via Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
Why Shares of Denali Therapeutics Are Up Monday
Analysts maintained their buy ratings on the clinical-stage biotech company. 
Via The Motley Fool
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer. 
Via Benzinga
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month. 
Via InvestorPlace
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
Biotech stocks targeting longevity could uncover the fountain of youth in coming years, offering a prime investment opportunity today. 
Via InvestorPlace
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a  
Via Benzinga
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
With longevity back in the news, many investors are wondering which biotech stocks to buy to best cash in on the growing trend. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker
Denali Therapeutics Inc (NASDAQ: DNLI) announced new interim results from the ongoing open-label, single-arm Phase 1/2 study of DNL310 IDS in children with  
Via Benzinga
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
Via Benzinga
Biogen Moves Deeper In Alzheimer's With Denali
Biogen exercised their rights to a Denali Alzheimer's drug. What does this mean longer term to the field and the companies? 
Via Talk Markets
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.